

Exosome-Based Drug Delivery Systems: Mechanisms, Design, and Therapeutic Applications

Krishnamoorthy S^{1*}, Chandru S¹, Hemalatha V¹, Iyyappan K¹, Dr. Selvaraj D²,
Dr. Sathish A³

¹ PG Research Scholar, Department of Pharmaceutics, GRD College of Pharmacy, Thiruvallur, Affiliated to The Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

² Professor and HOD, Department of Pharmaceutics, GRD College of Pharmacy, Thiruvallur, Affiliated to The Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

³ Professor cum Principal, GRD College of Pharmacy, Thiruvallur, Affiliated to The Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

Corresponding Author: Krishnamoorthy S

Date of Submission: 28-04-2026

Date of Acceptance: 07-05-2026

ABSTRACT: Exosomes are nanoscale extracellular vesicles (30–150 nm) that act as natural intercellular communication mediators by carrying bioactive cargos such as proteins, lipids, nucleic acids, and small compounds produced by endosomal pathway of different cell types. They are superior to synthetic nanoparticles for targeted drug delivery, especially in cancer therapy, regenerative medicine, and the treatment of neurological and infectious diseases, due to their intrinsic low immunogenicity, biological stability, and capacity to cross physiological barriers like the blood-brain barrier. Preclinical research shows that mesenchymal stem cell-derived exosomes are an effective way to deliver drugs like paclitaxel, doxorubicin, and gene-editing tools to tumors while minimizing off-target effects and encouraging tissue regeneration. Exosome-mediated delivery of atorvastatin for glioblastoma and cisplatin for lung cancer are two examples of the oncology, inflammation, and post-surgical recovery applications being investigated in clinical studies. Despite encouraging adaptability, issues with standardization, biodistribution optimization, scalable production, and regulatory compliance still exist. In order to improve precision medicine, future developments will focus on hybrid exosome designs, microfluidic isolation, and thorough safety evaluations. When biological and manufacturing challenges are resolved, exosome-based devices have revolutionary potential to overcome traditional delivery limitations.

KEYWORDS: Exosomes, targeted drug delivery, cancer therapy.


I. INTRODUCTION

Nanosized extracellular vesicles called exosomes, which are released by a variety of cell types, have become important intercellular communication mediators with growing applications in treatments and diagnostics. Their special capacity to transport bioactive substances like proteins, lipids, and nucleic acids makes them attractive options for targeted medication administration, cancer treatment, and regenerative medicine. Strong techniques for their isolation and characterisation, creative engineering to improve their therapeutic potential, and thorough preclinical and clinical assessments are all necessary for the development of exosome-based therapies.

CHARACTERISTICS AND ADVANTAGES OF EXOSOME-BASED DELIVERY

Exosomes are nanosized vesicles (30–150 nm) that are perfect for delivering therapeutic drugs since they are naturally able to transport molecular payload. They exhibit low immunogenicity, excellent stability in biological fluids, and innate targeting capabilities derived from their parent cells. Exosomes, in contrast to synthetic nanoparticles, can pass through physiological barriers like the blood-brain barrier and escape quick clearance, allowing delivery to areas that are typically difficult to reach. Precision

medicine applications are made possible by their cargo versatility, which includes tiny molecules, RNA, proteins, and gene-editing tools. [1], [2]



Structure of Exosome

BIOLOGY OF EXOSOMES

The endosomal system of cells is the source of exosomes. They can impact neurological and infectious disease processes, promote or inhibit tumor progression, and modulate immunological responses because their cargo reflects the physiological or pathological state of the parent cell. Exosomes carry their bioactive cargo and cause biological effects via interacting with recipient cells by surface receptor binding, fusion, or endocytosis. [3], [4]

BIOGENESIS OF EXOSOMES

Exosome biogenesis involves a number of tightly controlled processes, including:

1. Endocytosis and Early Endosome Formation: The process starts when the plasma membrane folds inward, creating early endosomes.
2. Multivesicular Body (MVB) Formation: As early endosomes develop into late endosomes, or MVBs, their limiting membrane folds inward to generate intraluminal vesicles (ILVs).
3. Cargo Sorting: ILVs preferentially integrate proteins, lipids, RNAs, and other compounds. The endosomal sorting complex required for transport (ESCRT) machinery and ESCRT-independent pathways involving lipids like ceramide and tetraspanins control this sorting.
4. MVB Fusion and Exosome Release: ILVs are released into the extracellular space as exosomes when MVBs fuse with the plasma membrane or with lysosomes for destruction.
5. Exosome Uptake: Recipient cells absorb released exosomes through receptor-mediated

interactions, endocytosis, or fusion with the plasma membrane. [3], [5], [6]

ESCRT-0, I, II, III, ALIX, syntenin, and Rab GTPases are important molecular mediators that coordinate vesicle trafficking, cargo sorting, and membrane remodeling. One prominent ESCRT-dependent mechanism is the syndecan-syntenin-ALIX pathway. [7], [8]

METHODS FOR EXOSOME ISOLATION AND CHARACTERIZATION

Ultracentrifugation, size exclusion chromatography, and microfluidics are examples of isolation techniques that balance yield, purity, and scalability. In order to maximize cargo encapsulation without losing exosome integrity, drug loading procedures range from passive incubation to active approaches like electroporation and sonication. Additionally, surface engineering techniques are used to improve circulation time and targeted specificity. [9], [10]

Exosomes must be effectively isolated and characterized in order to be studied and used in clinical settings. Although it takes a considerable amount of time and specialized equipment, differential ultracentrifugation (UC) is still the gold standard method because it can separate vesicles according to size and density. By placing samples over density gradients for more accurate separation, density centrifugation further improves purity. While immunoaffinity capture (IAC) uses antibodies that target exosomal surface antigens (such as CD9, CD63, CD81) to selectively isolate exosomes from heterogeneous samples, ultrafiltration (UF) uses membrane filters with specific pore sizes to isolate exosomes by size exclusion. New developments in size-based chromatography and microfluidic technology offer viable substitutes with improved scalability and efficiency. Polymer-based precipitation techniques offer a more straightforward process, but they run the danger of co-isolating impurities, which might affect sample purity. [11], [12], [13]

Nanoparticle tracking analysis (NTA) to ascertain size distribution, electron microscopy for morphological evaluation, and Western blot or flow cytometry to confirm exosomal markers are commonly used in the characterization of isolated exosomes. [11], [12]

ENGINEERING STRATEGIES FOR THERAPEUTIC EXOSOMES

Engineering techniques that concentrate on improving targeting specificity, cargo loading efficiency, and biological activity have been created in order to use exosomes as delivery vehicles and therapeutic agents. Cell engineering creates exosomes loaded with desired therapeutic cargo, such as proteins, nucleic acids, or tiny compounds, by genetically altering parent cells or by biochemically preconditioning them. As an alternative, direct exosome modification methods enhance tissue-specific delivery by coating the surface with targeted ligands or antibodies.


In order to include medications, RNA, or proteins after isolation, cargo loading techniques include electroporation, sonication, chemical transfection, and incubation with therapeutic compounds. Exosomal stability and functionality are further enhanced by fusion with other vesicles or hybridization with artificial nanoparticles. These engineering techniques seek to improve the therapeutic usability of natural exosomes by overcoming their intrinsic drawbacks, such as their limited targeting and quick systemic clearance. Scaling these approaches for clinical-grade production while maintaining safety and repeatability still presents challenges. [14], [15], [16]

PRECLINICAL AND CLINICAL APPLICATIONS

Exosome-based drug delivery has applications in infectious diseases, cancer, neurological disorders, and regenerative medicine. Exosomes can minimize off-target effects by delivering RNA molecules or chemotherapeutic medicines to tumor cells. Their capacity to pass through the blood-brain barrier opens up new therapeutic options for neurological conditions. Exosomes generated from mesenchymal stem cells are being studied for their potential to repair tissue and reduce inflammation. Translational promise is indicated by ongoing clinical trials investigating these uses. [1], [17], [18]

Many physiological and pathological processes are regulated by exosomes. Exosomes derived from tumors, for instance, promote the growth and metastasis of cancer, while exosomes derived from macrophages

influence immunological responses. They indicate viral components and influence host immunity in viral infections. These results emphasize exosomes as therapeutic targets and biomarkers. [4], [19]



Applications of Exosomes

Exosomes are versatile in regenerative medicine, cancer treatment, immunomodulation, and drug delivery, according to preclinical study. In particular, exosomes generated from mesenchymal stem cells (MSCs) have demonstrated effectiveness in encouraging tissue repair, lowering inflammation, and modifying immunological responses in a variety of disease scenarios. Exosomes have two functions in oncology: they are delivery systems for gene treatments and chemotherapeutic drugs, as well as diagnostic biomarkers. They are promising candidates for targeted therapy because of their low immunogenicity and capacity to cross biological barriers.

Exosome-based treatments for cancer, chronic inflammatory diseases, and surgical recovery are being investigated in a number of clinical translation trials. Standardization of isolation procedures, dosage calculation, and thorough safety assessments continue to be significant obstacles despite encouraging outcomes. Exosomes' therapeutic potential depends on filling in these gaps to allow for scalable and repeatable clinical uses. [20], [21], [22]

Exosomes as the delivery vehicle for diverse types of therapeutic molecules

Therapeutics	Application	Delivery	Ref
--------------	-------------	----------	-----

Drug molecule	Disease	Exosome vehicle	Reference
Aspirin	Cancer	Nanoamorphous aspirin-loaded exosomes	23
Atorvastatin	Glioblastoma	Human endometrial stem cell-derived exosomes	24
Taxol	Cancer	MSC-derived exosomes	25
Doxorubicin	Cancer	Exosome-sheathed porous silicon nanoparticles	26
Cisplatin	Lung cancer	M1 macrophage secreted exosomes	27
Paclitaxel	Triple-negative breast cancer	Exosomes from bone marrow-derived mesenchymal stem cells	28
Gemcitabine	Pancreatic cancer	Autologous pancreatic cancer-derived exosomes	29
Fluorouracil	Colon cancer	Dendritic cell-derived exosomes	30

II. CHALLENGES

Despite advancement, there are still major obstacles to overcome. Low drug loading efficiency, diverse exosome populations, a lack of consistent isolation and characterisation procedures, and challenges in large-scale production are some of the obstacles. To increase therapeutic efficacy, in vivo stability and biodistribution must be optimized. Clinical translation is made more difficult by the ongoing evolution of regulatory rules. Furthermore, there are gaps in safe and efficient design because of poor understanding of exosome biology and immune system interaction. [2], [9], [31]

III. FUTURE DIRECTIONS

Exosome engineering for improved cargo loading, targeted delivery, and controlled release is the main focus of research. The synthesis of clinical-grade exosomes is being improved by developments in surface modification and microfluidic isolation. Hybrid exosomes that combine synthetic and natural properties are gaining popularity. It is crucial to keep researching exosome biodistribution, immunogenicity, and long-term safety. Although the incorporation of exosome-based technologies into frameworks for customized treatment appears promising, more validation through carefully planned clinical studies is necessary. [32], [33]

IV. CONCLUSION

Exosome-based drug delivery systems offer a versatile, natural platform with significant therapeutic potential for a variety of diseases. To fully realize their clinical usage, they must overcome technological, biological, and regulatory obstacles even if they have clear advantages over traditional delivery techniques. Future studies should focus on manufacturing uniformity, enhance cargo loading and targeting, and create safety profiles. The evolving field indicates that exosome-based treatments have the potential to revolutionize precision medicine with further development.

REFERENCES

- [1]. Sharma V, Mukhopadhyay CD. Exosome as drug delivery system: Current advancements. *Extracellular Vesicle*. 2024; 3:100032.
- [2]. Palakurthi SS, Shah B, Kapre S, Charbe N. A comprehensive review of challenges and advances in exosome-based drug delivery systems. *Nanoscale Adv*. 2024; 6:5803-5826
- [3]. Kalluri R, LeBleu VS. The biology, function and biomedical applications of exosomes. *Science*. 2020; 367:6478.
- [4]. Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. *Cell Biosci*. 2019; 9:19.
- [5]. Mathieu M, Martin-Jaular L, Lavie G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. *Nat Cell Biol*. 2019; 21(1):9-17.

- [6]. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol.* 2018; 19(4):213-28.
- [7]. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan–syntenin–ALIX regulates the biogenesis of exosomes. *Nat Cell Biol.* 2012; 14(7):677-85.
- [8]. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu Rev Cell Dev Biol.* 2014; 30:255-89.
- [9]. Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug delivery systems. *J Control Release.* 2021; 10(329):894-906.
- [10]. Tian J, Han Z, Song D, Peng Y, Xiong M. Engineered exosome for drug delivery: recent development and clinical applications. *Int J Nanomedicine.* 2023; 18:7923-7940.
- [11]. Li, X., et al. Current methods for exosome isolation and characterization: A comprehensive review. *Biomolecules.* 2023; 13(12): 2970.
- [12]. Abcam. (2023). Exosome isolation and detection. <https://www.abcam.com/en-us/knowledge-center/cell-biology/exosome-isolation-and-detection>
- [13]. Chen, Y., et al. Ultracentrifugation and related technologies in exosome isolation. *Advanced Healthcare Materials.* 2023; 10(5): 1800021.
- [14]. Hu, L., et al. Engineering strategies for therapeutic exosomes: Surface modification and cargo loading. *Advanced Materials.* 2023; 35(8): 2206785.
- [15]. Zhang, Q., et al. Engineered exosomes for targeted drug delivery: Progress and challenges. *Nature Biomedical Engineering.* 2023; 7(3): 312-324.
- [16]. Wang, J., et al. Advances in exosome engineering for drug delivery and therapy. *ACS Applied Materials & Interfaces.* 2022; 14(34): 38545-38560.
- [17]. Lee J, Lee JH, Chakraborty K, Hwang J, Lee YK. Exosome-based drug delivery systems and their therapeutic applications. *RSC Adv.* 2022; 12: 18475.
- [18]. Gutierrez-Millan C, Calvo Díaz C. Advances in exosomes based drug delivery systems. *Macromol Biosci.* 2021; 21: 2000269.
- [19]. Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiological processes. *Biochim Biophys Acta.* 2014; 1841(1):108-20.
- [20]. Wang, S., et al. Preclinical and clinical advances of exosome-based therapeutics. *Stem Cell Research & Therapy.* 2023; 14(1): 123.
- [21]. Lee, C., et al. Mesenchymal stem cell-derived exosomes in regenerative medicine and cancer therapy. *Biotechnology Advances.* 2023; 61: 108045.
- [22]. Chen, H., et al. Clinical applications of exosomes: Current status and future perspectives. *Frontiers in Bioengineering and Biotechnology.* 2025; 13: 1671963.
- [23]. Tran PHL, Wang T, Yin W, Tran TTD, Barua HT, Zhang Y, Midge SB, Nguyen TNG, Lee B-J, Duan W. Development of a nanoamorphous exosomal delivery system as an effective biological platform for improved encapsulation of hydrophobic drugs. *Int J Pharm.* 2019; 566:697–707.
- [24]. Nooshabadi VT, Khanmohammadi M, Shafei S, Banafshe HR, Malekshahi ZV, Ebrahimi-Barough S, Ai J. Impact of atorvastatin loaded exosome as an anti-glioblastoma carrier to induce apoptosis of U87 cancer cells in 3D culture model. *Biochem Biophys Rep.* 2020; 23:100792.
- [25]. Melzer C, Rehn V, Yang Y, Bähre H, Jvd O, Hass R. Taxol-loaded MSC-derived exosomes provide a therapeutic vehicle to target metastatic breast cancer and other carcinoma cells. *Cancers (basel)* 2019; 11:798.

- [26]. Yong T, Zhang X, Bie N, Zhang H, Zhang X, Li F, Hakeem A, Hu J, Gan L, Santos HA, Yang X. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. *Nat Commun.* 2019; 10(10):3838. [biosciences/articles/10.3389/fmolb.2025.1583992/full](https://doi.org/10.3389/fmolb.2025.1583992/full)
- [27]. Li J, Li N, Wang J. M1 macrophage-derived exosome-encapsulated cisplatin can enhance its anti-lung cancer effect. *Minerva Med.* 2020
- [28]. Kalimuthu S, Gangadaran P, Rajendran RL, Zhu L, Oh JM, Lee HW, Gopal A, Baek SH, Jeong SY, Lee SW, Lee J, Ahn BC. A new approach for loading anticancer drugs into mesenchymal stem cell-derived exosome mimetics for cancer therapy. *Front Pharmacol.* 2018; 9:1116.
- [29]. Li Y-J, Wu J-Y, Wang J-M, Hu X-B, Cai J-X, Xiang D-X. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. *Acta Biomater.* 2020; 101:519–530.
- [30]. Xu M, Chen Q, Li J, Peng L, Ding L. Dendritic cell-derived exosome-entrapped fluorouracil can enhance its anti-colon cancer effect. *J BUON.* 2020; 25:1413–1422.
- [31]. Sen S, Xavier J, Kumar N, Ahmad MZ, Ranjan OP. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. *3 Biotech.* 2023; 13(3):101.
- [32]. Nature Communications. Despite the current technical challenges related to exosome preparation and the efficiency of cargo loading, exosomes have promising therapeutic potential as a new type of drug delivery system. 2024. Available from: <https://www.nature.com/articles/s12276-024-01201-6>
- [33]. *Frontiers in Molecular Biosciences.* This review spans research developments from 2010 to 2025, covering the engineering of exosomes to optimize cargo loading and targeting specificity. 2025. Available from: <https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1583992/full>